Related references
Note: Only part of the references are listed.SARS-CoV-2 Mpro inhibitors and activity-based probes for patient-sample imaging
Wioletta Rut et al.
NATURE CHEMICAL BIOLOGY (2021)
Repurposed Antiviral Drugs for Covid-19-Interim WHO Solidarity Trial Results
NEW ENGLAND JOURNAL OF MEDICINE (2021)
AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 In Vitro and a Promising Oral Antiviral for Treatment of COVID-19
Steven S. Good et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
A Comparative Analysis of SARS-CoV-2 Antivirals Characterizes 3CLpro Inhibitor PF-00835231 as a Potential New Treatment for COVID-19
Maren de Vries et al.
JOURNAL OF VIROLOGY (2021)
SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801
Angela Wahl et al.
NATURE (2021)
SARS-CoV-2 M-pro inhibitors with antiviral activity in a transgenic mouse model
Jingxin Qiao et al.
SCIENCE (2021)
A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication
Shin-ichiro Hattori et al.
NATURE COMMUNICATIONS (2021)
α-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design, Synthesis, and Activity Assessment
Linlin Zhang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
A new coronavirus associated with human respiratory disease in China
Fan Wu et al.
NATURE (2020)
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Peng Zhou et al.
NATURE (2020)
Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors
Linlin Zhang et al.
SCIENCE (2020)
Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors
Zhenming Jin et al.
NATURE (2020)
Organic Cation Transporters (OCTs) in EpiAirway™, a Cellular Model of Normal Human Bronchial Epithelium
Amelia Barilli et al.
BIOMEDICINES (2020)
A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice
Sarah R. Leist et al.
CELL (2020)
Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing
Laura Riva et al.
NATURE (2020)
Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19
Robert L. Hoffman et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Origin and evolution of pathogenic coronaviruses
Jie Cui et al.
NATURE REVIEWS MICROBIOLOGY (2019)
A Journey around the Medicinal Chemistry of Hepatitis C Virus Inhibitors Targeting NS4B: From Target to Preclinical Drug Candidates
Rolando Cannalire et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy
Thanigaimalai Pillaiyar et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS
Arun K. Ghosh et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Design and synthesis of new tripeptide-type SARS-CoV 3CL protease inhibitors containing an electrophilic arylketone moiety
Sho Konno et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2013)
Design, synthesis, and bioevaluation of viral 3C and 3C-like protease inhibitors
Allan M. Prior et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
Development of potent dipeptide-type SARS-CoV 3CL protease inhibitors with novel P3 scaffolds: Design, synthesis, biological evaluation, and docking studies
Pillaiyar Thanigaimalai et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2013)
Design, synthesis and crystallographic analysis of nitrile-based broad-spectrum peptidomimetic inhibitors for coronavirus 3C-like proteases
Chi-Pang Chuck et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2013)
Pharmacokinetic/Pharmacodynamic Predictors of Clinical Potency for Hepatitis C Virus Nonnucleoside Polymerase and Protease Inhibitors
Micaela B. Reddy et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Broad-Spectrum Antivirals against 3C or 3C-Like Proteases of Picornaviruses, Noroviruses, and Coronaviruses
Yunjeong Kim et al.
JOURNAL OF VIROLOGY (2012)
Linking Crystallographic Model and Data Quality
P. Andrew Karplus et al.
SCIENCE (2012)
Data processing and analysis with the autoPROC toolbox
Clemens Vonrhein et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2011)
Overview of the CCP4 suite and current developments
Martyn D. Winn et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2011)
Development of a New Permeability Assay Using Low-Efflux MDCKII Cells
Li Di et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2011)
Molecular replacement with MOLREP
Alexei Vagin et al.
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY (2010)
Features and development of Coot
P. Emsley et al.
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY (2010)
Darunavir A Review of its Use in the Management of HIV Infection in Adults
Kate McKeage et al.
DRUGS (2009)
Evaluating the 3C-like protease activity of SARS-Coronavirus: Recommendations for standardized assays for drug discovery
Valerie Grum-Tokars et al.
VIRUS RESEARCH (2008)
Phaser crystallographic software
Airlie J. McCoy et al.
JOURNAL OF APPLIED CRYSTALLOGRAPHY (2007)
Automated ligand placement and refinement with a combined force field and shape potential
S. Wlodek et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2006)
Validated assays for human cytochrome P450 activities
RL Walsky et al.
DRUG METABOLISM AND DISPOSITION (2004)
Coronavirus main proteinase (3CLpro) structure:: Basis for design of anti-SARS drugs
K Anand et al.
SCIENCE (2003)
Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding
MJ Banker et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2003)
Lopinavir/ritonavir - A review of its use in the management of HIV infection
RS Cvetkovic et al.
DRUGS (2003)
Molecular properties that influence the oral bioavailability of drug candidates
DF Veber et al.
JOURNAL OF MEDICINAL CHEMISTRY (2002)
Evaluation of the rodent micronucleus assay by a 28-day treatment protocol: Summary of the 13th Collaborative Study by the Collaborative Study Group for the Micronucleus Test (CSGMT)/Environmental Mutagen Society of Japan (JEMS)-Mammalian Mutagenicity Study Group (MMS)
S Hamada et al.
ENVIRONMENTAL AND MOLECULAR MUTAGENESIS (2001)
Structure-based design of ketone-containing, tripeptidyl human rhinovirus 3C protease inhibitors
PS Dragovich et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2000)
Share Paper
